
Cellectis and Cytovia in US$760m licence deal
Cytovia Therapeutics, Inc. and French Cellectis SAS have struck a licence deal to combine their different expertises in allogenic cancer cell...

BioVersys gets €20m EIB loan to develop novel antibiotics
The venture debt loan is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the European Union’s research and...

Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...

Novel strategy targets chronic liver diseases
The approach published in Nature Cancer leads to a cell-toxic accumulation of saturated fatty acids that drives tumour cells into apoptosis. HCC...

EMA recommends to continue AZD1222 vaccinations
After the stops of AstraZeneca's COVID-19 vaccine or specific batches of it in 13 EU member states, the EU regulatory authority EMA has analysed the...

Rentschler Biopharma launches gene therapy subsidiary
Monoclonal antibody specialist Rentschler Biopharma SE is moving forward with the expansion of its geographic footprint and technological porttfolio....

EU life science PPPs face less budget in Horizon Europe
The EU’s Public-Private Partnerships (PPPs), which have been under fire by the European Parliament and were renamed into ‘European Partnerships‘, are...